|
Dr. Joachim Schupp is Vice President, Medical Affairs and has served in this role since joining the Company in August, 2006. Dr. Schupp has more than 20 years experience in the global pharmaceutical industry. From October 2004 until August 2006, Dr. Schupp served as Vice President of Clinical Data Services and Clinical Solutions at ProSanos Corporation, a company specialized in the capture, integration and analysis of healthcare related data with focus on post-approval and pharmacovigilance studies. From January 1997 until September 2004, he was Global Project Leader at Novartis Pharma AG of Basel, Switzerland where he was responsible for life cycle management of numerous projects and compounds in oncology, dermatology and wound healing, including several first-of-kind therapeutics. In this executive director position within project management, his team leadership is credited for the market approval of several drugs, including Femara� in the US and EU for breast cancer and Apligraf� in the US for venous and diabetic ulcers, and for the international development of Exjade�, recently approved for transfusional hemosiderosis. Dr. Schupp served at Ciba-Geigy AG (later merged with Sandoz to form Novartis in 1996) from October 1985 until December 1996 as Medical Advisor/Clinical Research Physician and International Team Leader/Director of Clinical Research. Dr. Schupp received several prestigious awards at Ciba and Novartis for his contributions. He served on the faculty at the University of Pretoria, South Africa from January 1984 until February 1986 after receiving his M.D. from the Free University of Berlin. | 